Opendata, web and dolomites

AND-PD SIGNED

COMORBIDITY MECHANISMS OF ANXIETY AND PARKINSON’S DISEASE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AND-PD project word cloud

Explore the words cloud of the AND-PD project. It provides you a very rough idea of what is the project "AND-PD" about.

prove    degeneration    causative    genetic    depression    phenotype    samples    nucleus    experiments    dorsal    morbidity    preclinical    biomarkers    counteract    treatment    dopamine    aberrant    emotional    raphe    link    encoding    functional    causality    morbid    molecular    investigates    function    dysfunction    dysfunctional    bridge    circuits    morbidities    pathological    underlie    cohort    mental    signs    neurotransmission    databases    anxiety    secondary    biobank    brain    diagnosis    imaging    dopaminergic    patient    neurotoxin    interventions    reproduce    beneficiaries    translational    inform    mechanisms    rodent    striatal    markers    comorbidities    damage    rna    correlate    alter    cells    primate    regions    neuropathology    retrospective    valence    fmri    neurons    central    models    gap    causalities    clinical    microcircuit    physiological    caused    selectively    human    pet    hypothesis    behavioural    drn    posits    assignment    motor    patients    co    serotonergic    anatomical    pd   

Project "AND-PD" data sheet

The following table provides information about the project.

Coordinator
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS 

Organization address
address: CALLE SERRANO 117
city: MADRID
postcode: 28006
website: http://www.csic.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 5˙995˙848 €
 EC max contribution 5˙995˙848 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) coordinator 630˙906.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 1˙058˙867.00
3    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) participant 820˙976.00
4    KING'S COLLEGE LONDON UK (LONDON) participant 748˙286.00
5    Motac France FR (Floirac) participant 690˙735.00
6    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) participant 531˙372.00
7    UNIVERSITE DE BORDEAUX FR (BORDEAUX) participant 531˙250.00
8    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 448˙984.00
9    TRANSINE THERAPEUTICS LIMITED UK (ROYSTON) participant 250˙000.00
10    MODUS RESEARCH AND INNOVATION LIMITED UK (EDINBURGH) participant 153˙845.00
11    FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA ES (PAMPLONA) participant 130˙625.00

Map

 Project objective

AND-PD investigates causative mechanisms of anxiety (with or without depression) as a non-motor co-morbidity of PD. The central hypothesis posits that degeneration of dopaminergic neurons in the dorsal raphe nucleus (DRN) affects the activity of serotonergic cells which could alter DRN microcircuit and neurotransmission to target brain regions encoding for emotional valence. Dysfunction of DRN circuits and aberrant assignment of emotional valence, secondary to dopamine loss in the DRN of PD patients, may underlie PD-related anxiety. Using models of mental comorbidities of PD, AND-PD will investigate functional changes in the DRN-striatal circuits and establish the link between anxiety phenotype and degeneration of dopaminergic neurons in the DRN. Findings will be used to inform pre-clinical (rodent, non-human primate and biobank samples) and clinical research (fMRI and PET imaging, behavioural analysis, retrospective cohort analysis) to identify and correlate causalities between dysfunctional DRN activity and co-morbid anxiety of PD. To prove causality, AND-PD will i) analyse anxiety in neurotoxin and genetic models of PD; ii) assess the physiological impact and behavioural effects of interventions that selectively reproduce the damage caused by PD in the DRN; and iii) determine the ability of RNA based approaches targeting the DRN to counteract anxiety associated with PD. To demonstrate the link in human patients, AND-PD will analyse patient databases and correlate measures of anxiety with: 1) signs of neuropathology in PD brain samples’ DRN and 2) clinical and functional biomarkers of dopamine and serotonergic function through DRN imaging in patients. AND-PD beneficiaries’ experience in translational research will help ‘bridge the gap’ between preclinical and clinical experiments and help identify new anatomical targets and markers (molecular, functional and pathological,) to support better diagnosis, management and treatment of co-morbidities in PD patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AND-PD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AND-PD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

SoNAR-Global (2019)

A Global Social Sciences Network for Infectious Threats and Antimicrobial Resistance

Read More  

ATHENA (2019)

Assays for the identification of Thyroid Hormone axis-disrupting chemicals: Elaborating Novel Assessment strategies

Read More